Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Allergic Conjunctivitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018Allergic Conjunctivitis Therapeutics Market is Forecast to Show Significant Growth up to 2018
By: Rajesh Gunnam 2010, and expects it to grow at a Compound Annual Growth Rate (CAGR) of 14.3% over the next eight years, to reach $2.8bn by 2018. The increase in disease awareness is anticipated to lead to a growth in the diagnosed and treated population which will be further complemented by rising compliance due to the availability of a sufficient number of treatment options including branded, generics and OTC (Over The Counter) products. This increase in the treated patient population, the increasing uptake of medications and the rising compliance will be the primary drivers for the growth of the allergic conjunctivitis therapeutics market in the future. There are no major pipeline products which are expected to drive the market. The major late stage products in the allergic conjunctivitis therapeutics pipeline are modified pollen extracts which only cater to a niche population. GlobalData`s research indicates that the current treatment options are focused on offering relief from the symptoms of allergic conjunctivitis such as itching,redness,and swelling, which it serves reasonably well. However, there is an unmet need in the market, albeit low, relating to relief from the chronic form of the disease, requiring the introduction of novel therapies. Despite this unmet need the allergic conjunctivitis therapeutics pipeline is weak with major late stage products being modified pollen extracts which cater only to a niche population. Therefore, these molecules will not affect a significant portion of the diseased population and will not fulfill the overall unmet need of the market relating to the severe form of the disease in chronic condition Aciex Therapeutics, Inc., Santen Pharmaceutical Co., Ltd., and Merck & Co., Inc. are predicted to be the key players in the future. GlobalData has profiled all of these companies as they hold important pipeline drugs in late stage clinical development for allergic conjunctivitis. The existing market landscape remains competitive, because the treatment of allergic conjunctivitis relies on established therapies such as antihistaminic, mast cell stabilizer, dual-action agents, corticosteroids and Non-Steroidal Anti-Inflammatory Drugs (NSAIDS). For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ The increase in the prevalence, diagnosed and treated population of allergic conjunctivitis is expected to boost the current market. The significant increase in the number of treated patients amongst the population is the principal driver of the allergic conjunctivitis therapeutics market, and this will continue to be so in the future. In the US, approximately 70 million people are suffering from allergic conjunctivitis and it is estimated that there will be a 20% growth in the number of treated patients each year. Hence, an increase in the treated patient population will lead to an increased use of therapeutic drugs. GlobalData, the industry analysis specialist, has released its new report, “Allergic Conjunctivitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global allergic conjunctivitis therapeutics market. The report identifies the key trends shaping and driving the global market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global allergic conjunctivitis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a global market intelligence services company providing information research and analysis products and services. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number